1-(tert-Butoxycarbonyl)-4-(p-toluenesulfonyloxy)piperidine → 5-(3,4-dimethoxyphenyl)-4-methyl-2-piperidin-4-yl-4-propyl-2,4-dihydro-3H-pyrazol-3-one
反応式
[CH3:1][O:2][C:3]1[CH:4]=[C:5]([C:11]2[C:12]([CH3:20])([CH2:17][CH2:18][CH3:19])[C:13](=[O:16])[NH:14][N:15]=2)[CH:6]=[CH:7][C:8]=1[O:9][CH3:10].CC1C=CC(S(O[CH:32]2[CH2:37][CH2:36][N:35](C(OC(C)(C)C)=O)[CH2:34][CH2:33]2)(=O)=O)=CC=1>>[CH3:1][O:2][C:3]1[CH:4]=[C:5]([C:11]2[C:12]([CH3:20])([CH2:17][CH2:18][CH3:19])[C:13](=[O:16])[N:14]([CH:32]3[CH2:37][CH2:36][NH:35][CH2:34][CH2:33]3)[N:15]=2)[CH:6]=[CH:7][C:8]=1[O:9][CH3:10]参加物
3
実験手順
Prepared analogously as described for the example B1 (Alternative 1) using 5-(3,4-dimethoxyphenyl)-4-methyl-4-propyl-2,4-dihydro-3H-pyrazol-3-one (compound C8) and tert-butyl 4-(Toluene-4-sulfonyloxy)-piperidine-1-carboxylate (compound E1) as starting compounds resulting in the hydrochloride salt of the title compound. (compound B8*HCl)